stop nasacort aq and use singulair instead??

On June 12, 2009, the FDA announced that in April 2009, they completed their review of neuropsychiatric events, (mood and behavioral changes) associated with SINGULAIR (montelukast) and other drugs that act through the leukotriene pathway. FDA stated that: "Neuropsychiatric events have been reported in some patients taking montelukast (Singulair), zafirlukast (Accolate), and zileuton (Zyflo and Zyflo CR). FDA has requested that manufacturers include a precaution in the drug prescribing information (drug labeling)." The reported neuropsychiatric events include postmarket cases of agitation, aggression, anxiousness, dream abnormalities and hallucinations, depression, insomnia, irritability, restlessness, suicidal thinking and behavior (including suicide), and tremor. FDA also advised that: "Patients and healthcare professionals should be aware of the potential for neuropsychiatric events with these medications. Patients should talk with their healthcare providers if these events occur. Healthcare professionals should consider discontinuing these medications if patients develop neuropsychiatric symptoms." Visit Parents United for Pharmaceutical Safety and Accountability's website: www.parentsforsafety.org for more information and our response to the FDA's announcement.